Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Abeona Therapeutics (ABEO) over the last 4 years, with Q3 2025 value amounting to $1.4 million.

  • Abeona Therapeutics' Gains from Sales and Divestitures rose 4324.5% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 4324.5%. This contributed to the annual value of $1.0 million for FY2024, which is 27305.41% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Gains from Sales and Divestitures of $1.4 million as of Q3 2025, which was up 4324.5% from $500780.0 recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Gains from Sales and Divestitures ranged from a high of $1.4 million in Q3 2025 and a low of $27526.0 during Q4 2022
  • For the 4-year period, Abeona Therapeutics' Gains from Sales and Divestitures averaged around $567534.2, with its median value being $500780.0 (2025).
  • In the last 5 years, Abeona Therapeutics' Gains from Sales and Divestitures skyrocketed by 88288.89% in 2023 and then tumbled by 3884.48% in 2025.
  • Abeona Therapeutics' Gains from Sales and Divestitures (Quarter) stood at $27526.0 in 2022, then skyrocketed by 882.89% to $270550.0 in 2023, then soared by 273.05% to $1.0 million in 2024, then skyrocketed by 38.26% to $1.4 million in 2025.
  • Its Gains from Sales and Divestitures was $1.4 million in Q3 2025, compared to $500780.0 in Q2 2025 and $68167.0 in Q1 2025.